YMYihao Mao

Yihao Mao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yihao Mao has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Peng Zheng

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, People's Republic of China

    3 shared publications
  • Dexiang Zhu

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China

    2 shared publications
  • Jianmin Xu

    Wentao Tang, MD, PhD and Jianmin Xu, MD, PhD, Department of Colorectal Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, Shanghai Engineering Research Center of Colorectal Cancer Minimally Invasive Technology, Shanghai, China

    2 shared publications
  • Liangliang Yang

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China

    2 shared publications
  • Meiling Ji

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China

    2 shared publications
  • Qingyang Feng

    Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China

    2 shared publications

Latest Publications

  • Open Access

    Short-Term Traffic Flow Prediction Method Based on Spatio-Temporal Characteristics of Complex Road Network

    by Huawei Zhu, Yihao Mao, Yiming Zhao, Liyuan Shi, Yanli Shao


  • Open Access

    Exploration of exact significance of lymph node ratio and construction of a novel stage in colon cancer with no distant metastasis

    by Yang Lv, Qing-Yang Feng, Song-Bin Lin, Yi-Hao Mao, Yu-Qiu Xu, Peng Zheng, Liang-Liang Yang, Guo-Dong He, Jian-Min Xu

    Aim: Lymph node ratio (LNR) seems to be more precise than classic N stage in classifying cancer stage. Thus, we aim to construct a modified classification system based on LNR for colon cancer without distant metastasis. Methods: This study enrolled two independent cohorts of patients. The primary cohort enrolled 2,152 patients from 2008 to 2013 in Zhongshan Hospital, Fudan University. The validation cohort consisted of 77,406 patients from the Surveillance, Epidemiology, and End Results (SEER) registry from 2004 to 2014. The inclusion criteria were: pathologically confirmed colon cancer, and American Joint Committee on Cancer (AJCC) stage I/II/III. The exclusion criteria included: incomplete follow-up information, rectal cancer, and multiple primary sites. The prognostic value of LNR for overall survival was evaluated. The cutoff value of LNR was determined by the X-tile. Predictive performance of modified classification was determined by the concordance index. Results: After analysis, 0.05 and 0.50 were determined as the best threshold values of LNR. A value of 0.50 was reclassified as the mN0, mN1 and mN2 stage. A modified classification based on mN0, mN1, and mN2 was further constructed for stage I/II/III colon cancer. C-index of the modified classification was statistically more precise than AJCC classification (0.687 versus 0.605, PPConclusion: The clinical value of LNR level was preferable to classic N stage in colon cancer patients. Our proposed classification based on LNR and AJCC T category can effectively differentiate patients with varied survival outcomes.


  • Open Access

    Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer

    by Yihao Mao, Qingyang Feng, Peng Zheng, Liangliang Yang, Tianyu Liu, Yuqiu Xu, Dexiang Zhu, Wenju Chang, Meiling Ji, Li Ren, et al.

    Purpose: Tumor purity is defined as the proportion of cancer cells in the tumor tissue. The impact of tumor purity on colon cancer (CC) prognosis, genetic profile, and microenvironment has not been thoroughly accessed. Materials and methods: Clinical and transcriptomic data from three public datasets, GSE17536/17537, GSE39582, and TCGA, were retrospectively collected (n=1,248). Tumor purity of each sample was inferred by a computational method based on transcriptomic data. Survival-related analyses were performed on microarray dataset containing GSE17536/17537 and GSE39582 (n=794), whereas TCGA dataset was utilized for subsequent genomic analysis (n=454). Results: Right-sided CC patients showed a significantly lower tumor purity. Low purity CC conferred worse survival, and tumor purity was identified as an independent prognostic factor. Moreover, high tumor purity CC patients benefited more from adjuvant chemotherapy. Subsequent genomic analysis found that the mutation burden was negatively associated with tumor purity, with only APC and KRAS significantly more mutated in high purity CC. However, no somatic copy number alteration event was correlated with tumor purity. Furthermore, immune-related pathways and immunotherapy-associated markers (programmed cell death protein 1 [PD-1], programmed death-ligand 1 [PD-L1], cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], Lymphocyte-activation gene 3 [LAG-3] and T-cell immunoglobulin and mucin-domain containing-3 [TIM-3]) were highly enriched in low purity samples. Notably, the relative proportion of M2 macrophages and neutrophils, which indicated worse survival in CC, was negatively associated with tumor purity. Conclusion: Tumor purity exhibited potential value for CC prognostic stratification as well as adjuvant chemotherapy benefit prediction. The relative worse survival in low purity CC may attribute to higher mutation frequency in key pathways and purity-related microenvironmental changing.


  • Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer

    by Yihao Mao, Qingyang Feng, Peng Zheng, Liangliang Yang, Dexiang Zhu, Wenju Chang, Meiling Ji, Guodong He, Jianmin Xu

    The role of mast cells (MCs) in colorectal cancer (CRC) progression was controversial. Thus, our study was designed to evaluate the prognostic value of MCs as well as their correlation with immune microenvironment. A retrospective cohort of CRC patients of stages I–IV was enrolled in our study. Consecutive patients (854) were divided into training set (427 patients) and validation set (427 patients) randomly. The findings were further validated in a GEO cohort, GSE39582 (556 patients). The mast cell density (MCD) was measured by immunohistochemical staining of tryptase or by CIBERSORT algorithm. Low MCD predicted prolonged overall survival (OS) in training and validation set. Moreover, MCD was identified as an independent prognostic indicator in both sets. Better stratification for CRC prognosis can be achieved by building a MCD based nomogram. The prognostic role of MCD was further validated in GSE39582. In addition, MCD predicted improved survival in stages II and III CRC patients receiving adjuvant chemotherapy (ACT). Multiple immune pathways were enriched in low MCD group while cytokines/chemokines promoting anti‐tumor immunity were highly expressed in such group. Furthermore, MCD was negatively correlated with CD8+ T cells infiltration. In conclusion, MCD was identified as an independent prognostic factor, as well as a potential biomarker for ACT benefit in stages II and III CRC. Better stratification of CRC prognosis could be achieved by building a MCD based nomogram. Moreover, immunoactivation in low MCD tumors may contributed to improved prognosis.